Disease landscape

Small Cell Lung Cancer clinical trials

Get alerts when Small Cell Lung Cancer trials change

467 active trials 248 recruiting 64 Phase 3 263 sponsors 59 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-09-05

What changed in the last 30 days showing 40 of 59 changes on 20 trials

2026-09-04
Recruitment suspended
Recruitment suspended: Scheduled Interim Monitoring
Trial sites reduced: 415 → 411 locations
NCT04402788 Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment… · National Cancer Institute (NCI) · Phase 2/3
2026-08-14
Trial status changed: Completed → Terminated
Trial terminated: Accrual and drug manufacturing and supply were discontinued in 2025.
NCT02769962 Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With… · National Cancer Institute (NCI) · Phase 1/2
2026-09-04
Primary completion pushed: 2026-07 → 2027-01
Completion pushed: 2026-11 → 2027-04
NCT04699838 Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients… · Muhammad Furqan · Phase 2
2026-08-18
Primary completion pushed: 2029-02-09 → 2029-05-10
Completion pushed: 2029-02-09 → 2029-05-10
NCT06745323 A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in… · Amgen · Phase 2
2026-09-04
Primary completion pushed: 2029-12-31 → 2033-04-05
Completion pushed: 2030-10-31 → 2035-12-31
NCT07509333 MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients · West China Hospital
2026-08-12
Primary completion pushed: 2026-02 → 2026-11
Completion pushed: 2028-02 → 2028-11
NCT05856695 Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease… · Intergroupe Francophone de Cancerologie Thoracique · Phase 2
2026-08-18
Primary completion pushed: 2028-09-01 → 2030-09-01
Primary endpoint(s) modified
Enrollment increased: 45 → 105 participants
Completion pushed: 2030-09-01 → 2032-09-01
Trial arms changed: 2 → 4
NCT07139990 Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM) · University of Texas Southwestern Medical Center · Phase 1
2026-08-13
Primary completion pushed: 2025-09-30 → 2027-09-30
Completion pushed: 2026-09-30 → 2027-09-30
NCT05552846 Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of… · Ruijin Hospital
2026-08-22
Primary endpoint(s) modified
Recruitment opened
Enrollment increased: 56 → 299 participants
Trial sites expanded: 0 → 3 locations
Primary completion moved earlier: 2028-08 → 2027-08
Trial arms changed: 2 → 3
NCT07623369 A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors · Huahui Health · Phase 1
2026-08-28
Sponsor changed: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair → Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair
NCT01064466 Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms · Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair · Phase 2/3
2026-08-25
Recruitment opened
NCT07739758 A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve… · MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3
2026-08-26
Recruitment opened
NCT07654400 A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage… · Sichuan Baili Pharmaceutical Co., Ltd. · Phase 2
2026-08-26
Recruitment opened
NCT07488923 A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3… · Moonlight Bio, Inc · Phase 1
2026-08-22
Enrollment closed, study ongoing
Completion pushed: 2027-09-01 → 2027-10-01
NCT04429087 A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and… · Boehringer Ingelheim · Phase 1
2026-08-09
Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University → Second Affiliated Hospital, Zhejiang University, School of Medicine
NCT07061535 Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for… · Second Affiliated Hospital, School of Medicine, Zhejiang University · Phase 2
2026-08-09
Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University → Second Affiliated Hospital, Zhejiang University, School of Medicine
NCT06749691 Liposomal Irinotecan and Apatinib in ES-SCLC · Second Affiliated Hospital, School of Medicine, Zhejiang University · Phase 2
2026-09-03
Recruitment opened
NCT07783477 A Study of Armored CAR T Cells in People With Cancer · Memorial Sloan Kettering Cancer Center · Phase 1
2026-08-14
Trial completed
NCT03782207 A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions… · Hoffmann-La Roche
2026-08-22
Primary completion pushed: 2026-08-10 → 2026-09-30
Completion pushed: 2026-11-25 → 2026-12-25
NCT05963867 A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung… · Boehringer Ingelheim · Phase 1
2026-08-19
Trial completed
Completion moved earlier: 2026-10-31 → 2025-12-02
NCT03728361 Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell… · Dwight Owen · Phase 2

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-09-02 NCT07798947 A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in… Shanghai Hengrui Pharmaceutical Co., Ltd. new Phase 2
2026-08-31 NCT07795411 Prospective Multiomic Analysis in Small-Cell Lung Cancer Ohio State University Comprehensive Cancer Center new
2026-08-07 NCT07752875 A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53… LG Chem new Phase 1/2
2026-08-03 NCT07742800 Multi-Omics Prediction of Radiation Lung Injury in Immunotherapy-Treated Lung Cancer… HAN GUANG new
2026-07-27 NCT07728955 A Single-arm, Exploratory Clinical Study Evaluating the Efficacy and Safety of… Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University new Phase 3
2026-07-20 NCT07713732 TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors Treeline Biosciences, Inc. new Phase 1
2026-07-13 NCT07699237 A Multicenter Phase II Trial to Evaluate Rechallenge With Platinum-based Chemotherapy… University of Cologne new Phase 2
2026-07-01 NCT07677787 DLL3-Targeted PET/CT in Small Cell Lung Cancer The First Affiliated Hospital of Xiamen University new
2026-06-26 NCT07670442 Epigenomic Profiling of Circulating Cell-Free DNA (cfDNA) to Characterize the Dynamic… Assistance Publique - Hôpitaux de Paris new
2026-06-17 NCT07652736 A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European… BeOne Medicines new

Active trials by phase

Early Phase 1
6
Phase 1
75
Phase 1/2
66
Phase 2
169
Phase 2/3
6
Phase 3
58
Phase 4
6
Not charted: 81 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 467

NCT IDTitleSponsorStatusUpdated
Phase 4
NCT07744698 Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer… Anhui Provincial Cancer Hospital Recruiting 2026-08-04
NCT05874401 Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)… Pharmacosmos A/S Recruiting 2025-09-04
NCT06467786 Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer Tang-Du Hospital Recruiting 2024-06-21
NCT07485920 A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With… The Affiliated Hospital of Qingdao University Not Yet Recruiting 2026-03-20
NCT06951841 Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome… China Medical University, China Not Yet Recruiting 2025-04-30
NCT06931145 Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage… Peking Union Medical College Hospital Not Yet Recruiting 2025-04-23
Phase 3
NCT07218146 A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed… Zai Lab (Shanghai) Co., Ltd. Recruiting 2026-09-04
NCT07365241 A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706… AbbVie Recruiting 2026-09-02
NCT06712355 Safety and Efficacy of BNT327, an Investigational Therapy in Combination With… BioNTech SE Recruiting 2026-09-01
NCT06646276 A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed… Bristol-Myers Squibb Recruiting 2026-08-31
NCT07739758 A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve… MediLink Therapeutics (Suzhou) Co., Ltd. Recruiting 2026-08-24
NCT07778316 Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After… Amgen Recruiting 2026-08-21
NCT07472517 DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare… Boehringer Ingelheim Recruiting 2026-08-19
NCT04804644 Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain… NRG Oncology Recruiting 2026-08-17
NCT06801834 Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously… Gilead Sciences Recruiting 2026-08-12
NCT06203210 A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With… Daiichi Sankyo Recruiting 2026-08-06
NCT06095583 Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation… Shanghai Junshi Bioscience Co., Ltd. Recruiting 2026-07-27
NCT07502300 A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing… Sichuan Baili Pharmaceutical Co., Ltd. Recruiting 2026-07-27
NCT07005128 A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab… Amgen Recruiting 2026-07-16
NCT07473128 Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage… Pharmacosmos A/S Recruiting 2026-06-17
NCT06840704 Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer Hunan Cancer Hospital Recruiting 2026-04-02
NCT07015892 Dose-Escalation Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III… Instituto de Investigación Biomédica de Salamanca Recruiting 2026-03-31
NCT07010263 A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell… Akeso Recruiting 2026-03-05
NCT07189455 Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With… Suzhou Zelgen Biopharmaceuticals Co.,Ltd Recruiting 2026-01-05
NCT06457906 SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC Cancer Institute and Hospital, Chinese Academy of Medical Sciences Recruiting 2025-07-16
See all 467 active Small Cell Lung Cancer trials with filters →

Top sponsors by active trials in this area

National Cancer Institute (NCI) (19) · Amgen (14) · AstraZeneca (11) · Peking University Cancer Hospital & Institute (9) · Shanghai Pulmonary Hospital, Shanghai, China (9) · Boehringer Ingelheim (8) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (8) · Sichuan University (8) · Henan Cancer Hospital (6) · Merck Sharp & Dohme LLC (6)

Get alerts when Small Cell Lung Cancer trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free